Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2024.10.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antiobesity Medications in Patients With Heart Failure: A Clinical Protocol and Preliminary Single-Center Experience.
JACC Heart Fail
January 2025
Division of Cardiology, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA; Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:
GLP-1 and the Neurobiology of Eating Control: Recent Advances.
Endocrinology
January 2025
Centre for Cardiovascular and Metabolic Neuroscience; Dept of Neuroscience, Physiology and Pharmacology; University College London; UK.
Obesity is now considered a chronic relapsing progressive disease, associated with increased all-cause mortality that scales with bodyweight, affecting more than 1 billion people worldwide. Excess body fat is strongly associated with excess energy intake, and most successful anti-obesity medications (AOMs) counter this positive energy balance through the suppression of eating to drive weight loss. Historically, AOMs have been characterised by modest weight loss and side effects which are compliance-limiting, and in some cases life-threatening.
View Article and Find Full Text PDFPatterns of Weight Change Trajectories and Treatment Response in an Integrated Adult Primary Care Weight Management Practice.
Obes Sci Pract
February 2025
Division of General Internal Medicine Weill Cornell Medicine New York New York USA.
Introduction: Given the significant interindividual variable responses to interventions for obesity, the early identification of factors associated with a differential in weight loss would benefit real-world approaches in clinical practice.
Objective: This study evaluated the factors associated with individual variability in response to enrolling in a weight management program integrated into an academic-based primary care practice.
Methods: Data were retrospectively collected and analyzed for patients referred to a primary care-based weight management practice between 2012 and 2020.
Anti-inflammatory effect of Angiotensin 1-7 in white adipose tissue.
Adipocyte
December 2025
Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Obesity is a global health concern that promotes chronic low-grade inflammation, leading to insulin resistance, a key factor in many metabolic diseases. Angiotensin 1-7 (Ang 1-7), a component of the renin-angiotensin system (RAS), exhibits anti-inflammatory effects in obesity and related disorders, though its mechanisms remain unclear. In this study, we examined the effect of Ang 1-7 on inflammation of white adipose tissue (WAT) in dietary-induced obese mice.
View Article and Find Full Text PDFGlass "half full" on obesity and anti-obesity medication health communication.
Ann Behav Med
January 2025
Clinical Strategy, Teladoc Health, Purchase, NY 10577, United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!